Immatics Biotechnologies

Otterspace raises $3.7m in pre-seed funding, launches private beta to coordinate internet-native organizations with non-transferable tokens

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.

DeepL to elevate AI research with new investment

Calvin Risk closes a $1.5M Pre-Seed round to help companies deploy and manage trustworthy AI

LatticeFlow Secures $12 Million to Accelerate Platform to Eliminate AI Data and Model Blind Spots in Computer Vision

Otterspace raises $3.7m in pre-seed funding, launches private beta to coordinate internet-native organizations with non-transferable tokens

Demoboost raises EUR 1.7 million pre-seed to transform how software is bought and sold

Ledgy raises $22 million Series B to fund European expansion

Part 1 | Mastering Product Management Basics: Vision & Roadmap

ottonova defies difficult market conditions, raising EUR 34 million

i2x receives €11 million in funding and appoints second managing director

SumUp raises €590 million and celebrates 10 years of supporting small merchants

Immatics Biotechnologies

Get to know Immatics Biotechnologies